Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD)

Phase II study of XL184 (BMS 907351), an inhibitor of MET, VEGFR2, and RET, in patients (pts) with progressive glioblastoma (GB).

(2017) P. Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma

(2014) M. Nowosielski et al.   NEUROLOGY

Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

(2014) Olivier L. Chinot et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Somatic Genomic Landscape of Glioblastoma

(2013) Cameron W. Brennan et al.   CELL

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma

(2013) M. Axelson et al.   CLINICAL CANCER RESEARCH

Current and future directions for Phase II trials in high-grade glioma

(2013) Brian M Alexander et al.   Expert Review of Neurotherapeutics

Glioblastoma and Other Malignant Gliomas

(2013) Antonio Omuro   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Phase III Randomized Trial Comparing the Efficacy of Cediranib As Monotherapy, and in Combination With Lomustine, Versus Lomustine Alone in Patients With Recurrent Glioblastoma

(2013) Tracy T. Batchelor et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular neuro-oncology in clinical practice: a new horizon

(2013) Michael Weller et al.   LANCET ONCOLOGY

Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study

(2013) J. L. Boxerman et al.   NEURO-ONCOLOGY

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010

(2013) Q. T. Ostrom et al.   NEURO-ONCOLOGY

Recurrent Glioblastoma Treated with Bevacizumab: Contrast-enhanced T1-weighted Subtraction Maps Improve Tumor Delineation and Aid Prediction of Survival in a Multicenter Clinical Trial

(2013) Benjamin M. Ellingson et al.   RADIOLOGY

Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma

(2012) Dominik Sturm et al.   CANCER CELL

Phase III Trial of Chemoradiotherapy for Anaplastic Oligodendroglioma: Long-Term Results of RTOG 9402

(2012) Gregory Cairncross et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Procarbazine, Lomustine, and Vincristine Chemotherapy in Newly Diagnosed Anaplastic Oligodendroglioma: Long-Term Follow-Up of EORTC Brain Tumor Group Study 26951

(2012) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria

(2012) J. G. Perez-Larraya et al.   NEURO-ONCOLOGY

Does MR Perfusion Imaging Impact Management Decisions for Patients with Brain Tumors? A Prospective Study

(2011) C.P. Geer et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Glioblastoma: From Molecular Pathology to Targeted Treatment

(2011) Timothy F. Cloughesy et al.   Annual Review of Pathology-Mechanisms of Disease

An Interindividual Comparison of O-(2- [18F]Fluoroethyl)-L-Tyrosine (FET)– and L-[Methyl-11C]Methionine (MET)–PET in Patients With Brain Gliomas and Metastases

(2011) Anca-Ligia Grosu et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

The Potential of Relaxation-Weighted Sodium Magnetic Resonance Imaging as Demonstrated on Brain Tumors

(2011) Armin Michael Nagel et al.   INVESTIGATIVE RADIOLOGY

Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study

(2011) John F. de Groot et al.   JOURNAL OF CLINICAL ONCOLOGY

Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria

(2011) A. Radbruch et al.   NEURO-ONCOLOGY

Magnetic resonance imaging of the Amine–Proton EXchange (APEX) dependent contrast

(2011) Tao Jin et al.   NEUROIMAGE

Application of Novel Response/Progression Measures for Surgically Delivered Therapies for Gliomas

(2011) Michael A. Vogelbaum et al.   NEUROSURGERY

Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma

(2010) Wolfgang Wick et al.   JOURNAL OF CLINICAL ONCOLOGY

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity

(2010) Benjamin M. Ellingson et al.   JOURNAL OF MAGNETIC RESONANCE IMAGING

Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)

(2010) F. M. Iwamoto et al.   NEURO-ONCOLOGY

Bidimensional Measurements in Brain Tumors: Assessment of Interobserver Variability

(2009) James M. Provenzale et al.   AMERICAN JOURNAL OF ROENTGENOLOGY

End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Differentiation of Recurrent Glioblastoma Multiforme from Radiation Necrosis after External Beam Radiation Therapy with Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging

(2009) Ramon F. Barajas et al.   RADIOLOGY

Brain Tumor Imaging in Clinical Trials

(2008) J.W. Henson et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma

(2008) Teri N. Kreisl et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas

(2008) Kathleen R. Lamborn et al.   NEURO-ONCOLOGY

Malignant Gliomas in Adults

(2008) Patrick Y. Wen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Einfluss messtechnischer und morphologischer Faktoren auf die Genauigkeit der softwarebasierten MR-Tumorvolumetrie: eine Phantomstudie

(2008) S Rohde et al.   ROFO-FORTSCHRITTE AUF DEM GEBIET DER RONTGENSTRAHLEN UND DER BILDGEBENDEN VERFAHREN

Response criteria for glioma

(2008) A Gregory Sorensen et al.   Nature clinical practice. Oncology